Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
All patients recruited divided into two arms?SIB-IMRT or routine IMRT?in the routine arm?the prescription dose was 60Gy/2Gy/30f?and in the SIB arm ?60Gy was given to the field of the tumor and metastatic lymph nodes?50Gy was given to CR lesion and high-risk prevention. The physical advantages of SIB...
All patients recruited divided into two arms?SIB-IMRT or routine IMRT?in the routine arm?the prescription dose was 60Gy/2Gy/30f?and in the SIB arm ?60Gy was given to the field of the tumor and metastatic lymph nodes?50Gy was given to CR lesion and high-risk prevention. The physical advantages of SIB-IMRT are to reduce the radiation dose of organs that are at risk in the lungs, esophagus, and heart ensuring the adequate dose for tumor area at the same time. The investigators are carrying out this trial to compare the efficacy, safety, side effects, and type of failure of the two radiotherapy techniques, which will provide a new choice and reliable basis for the future dose-segmentation study of limited-stage small-cell lung cancer.
Tracking Information
- NCT #
- NCT04500145
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: zongmei zhou, PhD national cancer hospital
Get Well Soon